Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance

Gynecologic Oncology

Volumn 106, Issue 1, 2007, Pages 75-81

  Bamias, A ^a   Tsiatas, M L ^a   Kafantari, E ^a   Liakou, C ^a   Rodolakis, A ^a   Voulgaris, Z ^a   Vlahos, G ^a   Papageorgiou, T ^a   Tsitsilonis, O ^a   Bamia, C ^a   Papatheodoridis, G ^a   Politi, Ek ^a   Archimandritis, A ^a   Antsaklis, A ^a   Dimopoulos, M A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Immune response; NK T; Ovarian cancer; Tregs

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; CD69 ANTIGEN; FICOLL; HLA DR ANTIGEN; PLATINUM;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; ASCITES; CANCER CELL; CD4+ CD25+ T LYMPHOCYTE; CELL ACTIVATION; CELL ISOLATION; CELL POPULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MONONUCLEAR CELL; NATURAL KILLER T CELL; OVARY CANCER; PERITONEUM METASTASIS; PHENOTYPE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD3; ANTIGENS, CD56; ASCITES; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KILLER CELLS, NATURAL; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; T-LYMPHOCYTES, REGULATORY;

EID: 34250159834     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.02.029     Document Type: Article

References (27)

1. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., and Thun M.J. Cancer statistics 2003. Ca-Cancer J. Clin. 53 (2003) 5-26
2. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 (2003) 3194-3200
3. du Bois A., Luck H.J., Meier W., Adams H.P., Mobus V., Costa S., et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl. Cancer Inst. 95 (2003) 1320-1329
4. Ozols R.F. Management of advanced ovarian cancer consensus summary. Semin. Oncol. 27 Suppl. 7 (2000) 47-49
5. Holschneider C.H., and Berek J.S. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin. Surg. Oncol. 19 (2000) 3-10
6. + T-cell subpopulations in head and neck cancers. Clin. Cancer Res. 12 (2006) 465-472
7. + T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br. J. Cancer 85 (2006) 255-260
8. Zhang L., Conejo-Garcia J., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New Engl. J. Med. 348 (2003) 203-213
9. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10 (2004) 942-949
10. +/regulatory T cell ratio are associated with favourable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 18538-18543
11. Straub G., Guckel B., Wallwiener D., and Moldenhauer G. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3. Clin. Cancer Res. 5 (1999) 171-180
12. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61 (2001) 4766-4772
13. Markman M., and Bookman M.A. Second-line treatment of ovarian cancer. Oncologist 5 (2000) 26-35
14. Milliken D., Scotton C., Raju S., Balkwill F., and Wilson J. Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites. Clin. Cancer Res. 8 (2002) 1108-1114
15. Melioli G., Ferrari I., Casartelli G., and Ragni N. Lymphocytes isolated from the peritoneal fluid of women with advanced ovarian carcinoma differ significantly from autologous peripheral blood lymphocytes. Gynecol. Oncol. 48 (1993) 301-307
16. Santin A.D., Hermonat P.L., Ravaggi A., Bellone S., Roman J.J., Smith C.V., et al. Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer. Gynecol. Obstet. Invest. 51 (2001) 254-261
17. Yoshiji H., Kuriyama S., Hicklin D.J., Huber J., Yoshii J., Ikenaka Y., et al. The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model. Hepatol 33 (2001) 841-847
18. Feuerer M., Rocha M., and Bai L. Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. Int. J. Cancer 92 (2001) 96-105
19. + T cells to the antitumor immune response. J. Exp. Med. 210 (2005) 1-13
20. Wolf D., Wolf A.M., Rumpold H., Fiegl H., Zeimet A.G., Muller-Holzner E., et al. The expression of the regulatory T cell specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin. Cancer Res. 11 (2005) 8326-8331
21. Linn Y.C., and Hui K.M. Cytokine-induced killer cells: NK-like T cells with cytotoxic specificity against leukaemia. Leuk. Lymphoma 44 (2003) 1457-1462
22. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J. Immunol. 153 (1994) 1687-1696
23. Mantovani G., Maccio A., Pisano M., Versace R., Lai P., Eso S., et al. Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokines. Int. J. Cancer 71 (1997) 724-731
24. Zeimet A., Widschwendter M., Knabbe C., Fuchs D., Herold M., Muller-Holzner E., et al. Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J. Clin. Oncol. 16 (1998) 1861-1868
25. Emens L.A., and Jaffee E.M. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res. 65 (2005) 8059-8064
26. Karnbach C., Daws M.R., Niemi E.C., and Nakamura M.C. Immune rejection of a large sarcoma following cyclophosphamide and IL-12 treatment requires both NK and NK T cells and is associated with the induction of a novel NK T cell population. J. Immunol. 167 (2001) 2569-2576
27. Leemhuis T., Wells S., Scheffold C., Edinger M., and Negrin R.S. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol. Blood Marrow Transpl. 11 (2005) 181-187